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Summary A method for estimating both structural and functional vascular volumes in murine sarcomas is
described. Intact vessels were demonstrated by the presence of laminin, a basement membrane-associated
antigen, using an immunofluorescent technique. and functional vessels in the same sample by prior injection
with the DNA binding dye Hoechst 33342. No significant vascular effects were seen after melphalan but a
very pronounced decrease in both functional and structural vascular volume was seen after MISO. Combined
chemotherapy of a murine sarcoma with melphalan and MISO induced a rapid decrease in the functional
vascular volume, anid there was a resumption of blood flow prior to measurable regrowth. The fully regrown
tumour retained the vascular characteristics of untreated tumours of similar size.
The observed effects of ionizing radiation on tumour growth
are attributed by some authors to a direct cytotoxic action
on tumour cells, as well as an indirect cytotoxic action,
resulting from vascular and stromal damage (Thomlinson &
Craddock, 1966; Mattson & Peterson, 1979). Vascular
damage may also represent an important component in the
therapeutic effectiveness of hyperthermia, where the
increased sensitivity of tumour vasculature to heat could lead
to enhanced tumour cell kill (for review see Song, 1984). As
occlusion of the vasculature can alone lead to tumour
control or cure (Denekamp et al., 1983), the vascular
component of any form of therapy must not be
underestimated; indeed the vasculature itself may represent
an important target for therapy (Denekamp, 1984). In
contrast to radiation and hyperthermia, however, little is
known about the possible contribution of a vascular
component in chemotherapy; in general the effects are
considered the result of direct tumour cell kill.
In this study we have examined the effects of the
alkylating agent melphalan on the vasculature of a murine
sarcoma when used alone or in combination with the
radiosensitizer Misonidazole (MISO). MISO is known to
potentiate the effects of melphalan. The origins of this
phenomenon, known as 'chemosensitization', are not fully
understood. Among the possible mechanisms that have been
proposed are: that MISO is directly cytotoxic to hypoxic
cells, alters the pharmacokinetics of the cytotoxic drugs,
interferes with the repair of potentially lethal damage, or
depletes intracellular thiols; (For reviews see McNally, 1982;
Millar, 1982; Siemann, 1982; 1984). The present study was
carried out to determine whether a vascular component
could be attributed to the potentiation of melphalan
cytotoxicity by MISO.
Although many methods exist for studying structural and
functional parameters of normal tissues and tumours, in
general these methods do not distinguish patent vessels from
those which may be temporarily, or permanently, non
functional. We utilize here a method whereby, in the same
tumour sample, structural and functional information can be
obtained using a morphometric technique. The method relies
upon the identification of blood vessels by the
immunolluorescent demonstration of the glycoprotein
laminin, present in the blood vessel walls (Timpl et al.,
1979). This structural marker was used in parallel with a
functional fluorescent marker, bis-benzamide Hoechst 33342,
injected into the mouse prior to sacrifice. The actual
structural vascular volume as well as the proportion of
functional vessels could then be estimated.
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Materials and methods
Mice and tumours
All experiments were carried out on the sarcoma SA FA
grown in WHT/Gy f BSVS mice. This tumour arose
spontaneously at the Gray Laboratory and has been
maintained by serial passage in the inbred strain of origin.
The tumour is transplanted subcutaneously by trocar as
1 mm3 pieces on to the backs of mice. Histologically, the SA
FA tumour is poorly differentiated and anaplastic, and
metastasizes to the regional lymph nodes.
Drug treatments
Melphalan was first dissolved in 0.5ml of 2% HCI in
ethanol and then further diluted with 9.5ml sterile saline,
prior to administration. MISO was dissolved in sterile saline.
Both drugs were administered simultaneously i.p. according
to body weight of each animal; melphalan at a dose of
I0mgkg- 1 and MISO at I,000 mgkg- 1.
Tumnour nmeasurement and growtth delaY estimation
Tumour-bearing mice were treated with melphalan, MISO or
a combination of both when the geometric mean diameter
(GMD) of the tumour was -7.5mm. Tumours were then
measured in 3 orthogonal dimensions 2-3 times per week
and GMDs calculated. The investigator was unaware of
which treatment group was being measured. Tumour
response after treatment was assessed as the additional time
taken for the tumours to grow to 4mm above treatment size.
Hoechst 33342 staining of tumour blood vessels
At specific times after treatment, or when tumours had
reached specified sizes, mice were injected i.v. via the tail
vein with a solution of the fluorescent DNA-binding dye
Hoechst 33342 in a volume of 300,uI of sterile saline. Mice
were killed by cervical dislocation after injection and the
tumour rapidly excised and frozen in liquid nitrogen and
stored at -70°C. Preliminary experiments were carried out
to determine both optimal dosage of Hoechst 33342 and
optimal circulation time before sacrifice. A range of doses
from 5-40mgkg-1 and circulation times from 1 to 30 min
post injection were used.
Basement membrane staining ofblood vessels
The basement membrane (BM) of blood vessels in tumours
was visualised by the indirect immunofluorescence method,
using a rabbit antiserum to mouse laminin. The glycoprotein
laminin is a structural component of normal basement
membranes including those of blood vessels of all sizes
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(Timpi et al., 1979; Barsky et al., 1983). The frozen SA FA
tumours from mice previously injected with Hoechst 33342,
were sectioned at 6pm on a cryostat and sections allowed to
air dry at room temperature. Frozen sections were then
rehydrated in PBS and incubated for 20 min with normal
goat serum at 1/50 dilution in PBS. Sections were washed
briefly in PBS. A 1/50 dilution of a rabbit antiserum to
mouse laminin (EY laboratories) was then applied and
incubated for I h. After washing for IOmin against 3 changes
of PBS, a 1/50 dilution of a TRITC (tetra-methylrhodamine
isothiocyanate) - labelled Goat anti-rabbit IgG (Sigma) was
applied and incubated for a further I h. All incubations were
carried out at room temperature. After washing with PBS, a
drop of 10% glycerol in PBS was placed on each slide and a
cover slip mounted.
Assessment of ivascular volunme
Stained sections were observed with a Leitz microscope
equipped with epifluorescence, using either a UV filter to
observe the Hoechst 33342 staining, or the TRITC filter to
observe the BM staining. By this means both total blood
vessels, assuming they had intact basement membrane, and
total functional vessels, assessed by the presence of a
Hoechst 'halo', could be observed. Sections could be stored
in this form for several days at 4 C without significant loss
of staining, although any attempts to fix sections using
organic solvents such as acetone of ethanol usually resulted
in the loss of some or all Hoechst fluorescence.
Vascular volume was estimated, using both Hoechst
staining and basement membrane staining, by the Chalkley
point counting method (Chalkley, 1943). In brief, a grid
containing 25 randomly distributed spots was placed in the
microscope eyepiece and the number of times a spot fell
within a specified area, in this case within a vessel or on the
vessel wall, was scored. Repetition of this procedure over a
specified number of randomly chosen fields in the tumour
section will in theory give a figure closely approximating to
the proportion of total volume occupied by these structures.
All estimates were based upon the counting of a minimum of
40 fields randomly chosen from 2 sections, one from the
midline of the tumour and one halfway between the distal
edge and the midline. In the case of Hoechst staining, only
points falling within the central regions of the 'haloes' were
included in the estimation. All sections were scored 'blind',
each slide being labelled only with a mouse code number.
Most estimates of Hoechst and BM vascular volume were
based upon pooled data from 2 separate experiments. In the
case of early time points the means were based upon pooled
data from three experiments.
Results
Ef,cct of nelphalaan andS MISO oni tunmour growth
Melphalan alone caused a growth delay of - 3 days, whereas
the combination of melphalan and MISO caused a delay of
- 12 days. MISO alone had no effect on the growth of the
tumour.
Vascular i'olume ofcontrol tum1ourl-s
Vascular volume of tumours was estimated on the basis of
both basement membrane (BM) and Hoechst 33342 staining.
Figure a shows a fluorescence micrograph of a 6 pm frozen
section of SA FA tumour stained with anti-laminin and a
TRITC-conjugated second antibody. The BM antibody
stains the area immediately surrounding the putative blood
vessels in a linear continuous manner. There is little
background staining. Figure lb shows the same field viewed
with UV excitation for Hoechst 33342 fluorescence. The
Hoechst dye appears to concentrate in the nuclei of cells
surrounding a blood vessel, producing a 'halo' effect, and
has penetrated to a depth of 2-3 cells from the vessel. All
morphometric analysis was carried out on identical or
adjacent sections using two different fluorescence excitations.
The results of preliminary experiments indicated that the
optimal circulation time for Hoechst 33342 was I min.
Longer periods of 10min resulted in a loss of vessel
definition, but no significant change in assessment of
vascular volume. Varying the concentration of Hoechst
33342 over a range 10-40mgkg-1 had no significant effect
on estimation of vascular volume of tumours averaging
9mm GMD. A slight decrease in estimates of vascular
volume was observed however, in 7mm tumours with doses
up to 40mgkg-I of Hoechst 33342 (data not shown). All
Figure 1 (a) Fluorescence micrograph of a 6pm frozen section of the SA FA tumour stained by the indirect immunofluorescent
method with rabbit anti-mouse laminin and a fluorescein-conjugated second antibody (bar= 100pm). (b) The same field as (a)
viewed with UV excitation to visualize Hoechst 33342 perfusion. The mouse was sacrificed and the tumour excised I min after i.v.
injection of Hoechst dye at a dose of 40 mg kg- 1.CHEMOTHERAPY AND VASCULATURE 235
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Figure 2 (a) Growth curve for control SA FA. Each point
represents the mean of 6 mice+s.e. (b) BM (open symbol) and
Hoechst 33342 (closed symbol) estimates of the vascular volume
over the same period as the growth curve. Each point represents
the mean+ s.e. of between 3 and 8 mice.
subsequent experiments were carried out using Hoechst
33342 at 40mgkg-1.
Figure 2a shows the growth curve for control tumours
from treatment size to - 12mm mean diameter. Control
tumours took 12 days to reach 4 mm above treatment size.
Figure 2b shows the change with growth in vascular
volume assessed by Hoechst staining and BM staining. As
the tumours grew to 12mm GMD, the BM vascular volume
fell progressively from 10.9+0.9% to 8.5+0.9% (not
significantly different), whilst the Hoechst vascular volume
fell from 5.7+0.8% to 3.2+0.2% (significantly different,
P<0.05).
Effect ofmelphalan alone on vascular volume
Melphalan-treated tumours took 15 days to reach 4mm
above treatment size, showing a growth delay of -3 days
(Figure 3a).
Although there was a marked drop in BM vascular
volume within 6 days of treatment, this was not reflected in
the Hoechst vascular volume estimates which showed little
deviation from control values (Figure 3b).
Effect ofMISO alone on vascular volume
Figure 4a shows the growth curve for tumours treated with
MISO alone. MISO treatment produced no significant
growth delay.
The BM vascular volume of tumours dropped rapidly
within 2 days of treatment, and remained below control
values throughout the period of growth. The Hoechst
vascular volume also fell rapidly, but recovered by day 4 and
by the time tumours had reached approximately 12mm
GMD was essentially identical to controls (Figure 4b).
Effect ofmelphalan in combination with MISO on vascular
volume
Figure Sa shows the tumour response to the combined
treatment. This was the most effective treatment, tumours
taking approximately 24 days to reach 4mm above
treatment size.
Figure Sb shows the vascular volume estimates over this
time period. Both estimates of vascular volume dropped
Figure 3 (a) Growth curve of SA FA treated with melphalan
alone at 10mgkg-1. Dotted lines represent corresponding
control values. (b) Corresponding estimates of BM and Hoechst
vascular volumes.
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Figure 4 (a) Growth curves of SA FA treated with MISO alone
at 1000mgkg-1. (b) Corresponding estimates of BM and
Hoechst vascular volumes.
sharply within 1 day of treatment compared to control
values. After the initial drop, BM vascular volume remained
fairly constant until regrowth began. Hoechst vascular
volume, after reaching a minimum value- at day 2, -began to
increase until around day 14. From day 14 onwards, during
the regrowth period, the BM vascular volume estimate
increased, and by the time tumours had reached -12mm
GMD, both vascular volume estimates were strikingly
similar to those of the untreated tumours of the same size.
Discussion
Most techniques currently in use for investigating tumour
vasculature do not allow the study of both structure and
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Figure 5 Growth curves of SA FA treated with combined
melphalan (10mgkg-1) and misonidazole (1000mgkg-1). (b)
Corresponding estimates of BM and Hoechst vascular volumes.
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function in the same sample. Assumptions about changes in
vascular structure are frequently based upon induced
functional changes and vice versa. The use of contrast media,
such as India ink (Lewis, 1927) and colloidal carbon (Hilmas
& Gillette, 1973), or radio-opaque medium (Solesvik et al.,
1984; Margulis et al., 1961), although providing elegant
structural information about tumour vasculature, must
necessarily neglect those vessels which may not be available
to the contrast agent at the time of the experiment.
Conversely those methods which aim to determine vascular
volume, and other parameters, by purely histochemical
means (Tannock & Steel, 1969; Revesz & Siracka, 1984)
provide little information about the efJective functional
vascular volume. To some extent the method we have
described in this paper overcomes these problems, providing
not only information about the total volume of tumour
occupied by the vasculature, but also the fraction of vessels
which were functional within a minute of sacrifice.
Hoechst 33342 has proven a useful tool for outlining
vascular structures in tumours (Rheinhold & Visser, 1983),
for cell selection based upon distance from blood vessels
(Durand, 1982; Chaplin et al., 1985), and for estimation of
vascular volume (Smith et al., 1986). The dye is rapidly
taken up by endothelial cells (Rheinhold & Visser, 1983), as
well as tumour cells (Rheinhold & Visser, 1983; Chaplin et
al., 1985). However, diffusion is limited to within a few cell
layers of the blood vessels, for at least the first few hours
after injection (Olive et al., 1985). In our experiments, a one
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Figure 6 The ratio of Hoechst to BM vascular volume estimates vs. time, for (a) control (b) melphalan treated (c) MISO-treated
and (d) animals treated with combined melphalan and MISO. Hatched areas represent the limits of control values.
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minute time period was chosen as this gave good definition
of vessels (Figure 1 b), and subsequent measurements of
vascular space were not significantly altered by longer
exposure to the dye. This short exposure will naturally only
highlight vessels where blood flow is relatively fast and fail
to define vessels which have a stagnant flow. It is also likely
that differences will exist between tumour models,
particularly in view of their variable vascular characteristics,
and therefore the precise conditions described here may only
apply to the SA FA tumour.
The use of antibodies to BM markers represents perhaps
the most sensitive means of detecting small blood vessels in
normal and neoplastic tissues (Barsky et al., 1983). In human
sarcomas blood vessels of all sizes stain positively for
laminin and collagen type IV when specific antibodies are
used, whilst, in general other areas remain negative
(Birembaut et al., 1985). Antibodies to laminin will also
distinguish blood vessel and lymphatic capillaries, as the
latter lack laminin (Barsky et al., 1983). Unfortunately,
carcinomas frequently express laminin as a constitutive
product, not necessarily related to vascular structures
(Birembaut, 1985), and therefore the technique we describe
here can only readily be applied to sarcomas. In the case of
the SA FA sarcoma good vessel definition was obtained
(Figure la).
In our experiments both indicators of vascular volume
demonstrated a decrease as the control tumours grew,
although only in the case of the Hoechst vascular volume
was the change statistically significant (Figure 2).
Morphometric analyses by other authors have revealed
similar changes in some tumours (Vaupel, 1974, 1977;
Gullino, 1975), whereas in other tumours vascular volume
was seen to remain constant (Vogel, 1965). This decrease in
vascular volume with size has been attributed to a
progressive failure of the neovascularization process, or a
diminished quality of vasculature as the tumour expands.
The nutritive potential of the blood may also be
compromised in the long vessel loops needed to reach the
centre of large tumours. Falk (1978) has pointed out that
thin-walled vessels may collapse as the hydrostatic pressure
increases in the growing tumour. It has also been suggested
that the loss of effective vasculature may be due to the
differential in proliferation rates of endothelial cells and
neoplastic cells (Tannock, 1970; Hirst et al., 1982).
Thomlinson & Gray (1955) and Rubin & Casarett (1966a, b)
stressed the implication of this phenomenon for radio-
therapy, since a diminished vascular supply may lead to a
hypoxic, radioresistant fraction. The apparent diminution in
vascular volume with size may also be relevant to chemo-
therapy: Shipley et al. (1975), and more recently Smith et al.
(1985), have suggested that the availability of chemo-
therapeutic agents may be diminished in large tumours,
which may explain in part the observations of Steel &
Adams (1975) that larger Lewis lung carcinomas are more
resistant to cyclophosphamide treatment than smaller
tumours.
Melphalan alone had little effect on either estimate of
vascular volume (Figure 3), despite a three day growth delay
induced by the drug. MISO alone, on the other hand had a
dramatic effect on both Hoechst and BM vascular volume
estimates (Figure 4). This was an unexpected result and had
not previously been recognised. Indeed, there is little
information in the literature about possible vascular effects
of this drug. By contrast, MISO has been shown to increase
the vascular area in the subepithelium of the rabbit trachea
(Albertsson et al., 1985). Also, the decrease in heart rate,
respiration rate and body temperature that have been
observed in mice after high MISO doses (Gomer & Johnson,
1979; Chin & Rauth, 1981; Conroy et al., 1980) have been
postulated as resulting from a systemic vascular effect
(Conroy et al., 1980). These effects are transient however,
lasting only a few hours. The prolonged reduction in
vascular space seen in the present study could initially be a
passive response to a systemic vasodilation (a 'steal' effect),
but that does not explain the duration of the effect. Other
authors have speculated that vasodilators in general may
cause a relative decrease in tumour blood flow (Ackerman,
1972; Wickersham et al., 1977). However, we cannot rule out
the possibility that MISO, or toxic metabolites of MISO are
having a direct effect on the endothelial cells of the tumour
vasculature.
The tumoricidal effects of MISO as a single agent have
been attributed to its metabolism in hypoxic cells into a
toxic product. This cytotoxic effect has been demonstrated in
vitro by several groups (Hall & Roizin-Towle 1975; Stratford
& Adams, 1977) and has led to a wider appreciation of the
potential of bioreductive metabolism as an antitumour
approach. The very extensive necrosis seen in the KHT
tumour after high doses of MISO led Brown (1977) to
postulate that the toxic metabolite could diffuse to, and kill,
cells other than the hypoxic cells that had produced it. An
alternative explanation of the extensive necrosis would be
that it resulted from additional prolonged ischaemia as a
result of a MISO-induced vascular shutdown.
The combination of MISO and melphalan induced an
equally dramatic decrease in vascular volume estimates, but
this decrease persisted longer than that for MISO alone
(Figure 5). If MISO administered simultaneously with
melphalan reduces blood flow in the tumour, melphalan may
remain in contact with both endothelial and tumour cells
longer, resulting in increased cytotoxicity to both. Such a
hypothesis is supported by the observation (Randhawa et al.,
1985) that MISO at 1000mgkg-I significantly increases the
half-life of melphalan in the SA FA tumour and plasma of
WHT mice, and that maximum chemosensitization occurs
when the drugs are administered simultaneously (Randhawa
et al., unpublished). As our first time points are at 24h after
treatment, we are unable to say how rapid is the onset of
this vascular effect. We are currently investigating this topic
in more detail. The apparent reduction in vascular volume
estimates using the BM stain indicate that vessels must
actually collapse rather than simply becoming stagnant. If
the vessels flatten they will appear less often in a
morphometric analysis than dilated vessels. The possibility
that the laminin has been resorbed, or is failing to stain,
cannot be excluded, but this seems less likely than simple
collapse. In the regrowing tumour (after day 14), BM
vascular volume increased once more to a level similar to
that observed in control tumours.
In Figure 6 we have chosen to express the data as ratios
of Hoechst vascular volume to BM vascular volume. This
plot emphasises the point that under most conditions only a
fraction of the total available vascular space is functional. In
the case of control SA FA tumours (Figure 6a) this fraction
was 50% falling slightly (but not significantly) to 40%.
This was not an unexpected result: Using radio-isotope
techniques, Tannock & Steel (1969) have demonstrated that
there exists a certain proportion of blood in tumours which
does not exchange with that of the general circulation. Stasis
in these vessels may then be followed by thrombosis and
vessel occlusion (Gullino, 1975; Vaupel, 1977).
In melphalan-treated tumours the ratio of Hoechst
vascular volume to BM vascular volume followed a similar
pattern to that of controls (Figure 6b). After MISO or
combined treatment the ratios diminished dramatically
(Figure 6c, d) indicating that the efJective fraction of the
vascular space (as well as the total detectable volume) was
reduced as a result of treatment. At the time of regrowth of
the tumours treated with MISO and melphalan, the ratio
showed a small peak of perfusion (Figure 6d), although this
peak was not significantly different from control tumours of
the same size. It appears from our experiments with MISO
alone that a significant loss of vascular function can be
demonstrated without any measurable effect on growth rate.
Conversely, melphalan alone induces a small but significant
growth delay, without affecting the vascular volume of the238 J.C. MURRAY et al.
tumour. We conclude that the loss of effective vascular
volume in the combined therapy is not necessarily the
primary cause of measurable growth delay, and that the net
effect may be the result of a combination of some direct cell
kill, coupled with further cell death due to vascular
insufficiency.
The extent to which vascular effects of MISO can account
for chemosensitization by alkylating agents, the apparent
MISO-induced necrosis seen in some tumours (Brown, 1977),
or even the enhanced sensitivity of some normal tissues has
yet to be investigated. It is clear, however, that the influence
of MISO may be indirectly mediated via a physiological
response and cannot now be assumed to be a simple local
chemical action within individual hypoxic cells.
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